![Samir Chandrakant Patel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Samir Chandrakant Patel
Direktor/Vorstandsmitglied bei ARVO Foundation for Eye Research
Aktive Positionen von Samir Chandrakant Patel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ARVO Foundation for Eye Research | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Samir Chandrakant Patel
Ehemalige bekannte Positionen von Samir Chandrakant Patel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IVERIC BIO, INC. | Direktor/Vorstandsmitglied | 29.05.2013 | 13.01.2017 |
Gründer | 18.12.2009 | 13.01.2017 | |
Präsident | 05.01.2007 | 13.01.2017 | |
KIORA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | - | - |
AERIE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Mimetogen Pharmaceuticals, Inc.
![]() Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Direktor/Vorstandsmitglied | - | - |
Oldtech, Inc.
![]() Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Direktor/Vorstandsmitglied | 01.01.2000 | - |
Technik-/Wissenschafts-/F&E-Leiter | 01.01.2000 | - | |
Gründer | 01.01.2000 | - | |
The University of Chicago | Corporate Officer/Principal | 01.01.1991 | - |
Ausbildung von Samir Chandrakant Patel
Boston University | Undergraduate Degree |
UMass Chan Medical School | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Kanada | 2 |
Israel | 2 |
Operativ
Director/Board Member | 5 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
KIORA PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
IVERIC bio, Inc.
![]() IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Oldtech, Inc.
![]() Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
Mimetogen Pharmaceuticals, Inc.
![]() Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Health Technology |
Aerie Pharmaceuticals, Inc.
![]() Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
ARVO Foundation for Eye Research |
- Börse
- Insiders
- Samir Chandrakant Patel
- Erfahrung